Scarica l'app Stockscreener
13.08
1.79%
0.23
Dopo l'orario di chiusura:
12.52
-0.56
-4.28%
Precedente Chiudi:
$12.85
Aprire:
$12.85
Volume 24 ore:
4.94M
Relative Volume:
3.05
Capitalizzazione di mercato:
$1.12B
Reddito:
$139.71M
Utile/perdita netta:
$-209.36M
Rapporto P/E:
-5.0698
EPS:
-2.58
Flusso di cassa netto:
$-160.60M
1 W Prestazione:
-6.10%
1M Prestazione:
-17.99%
6M Prestazione:
-32.12%
1 anno Prestazione:
-33.60%
Intervallo 1D:
$12.75
$13.15
Intervallo di 1 settimana:
$12.75
$14.18
Portata 52W:
$12.75
$25.34
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
35 GATEHOUSE DRIVE, WALTHAM, MA
Confronta SNDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
13.08 | 1.12B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-06-28 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid FDA approvals - Investing.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors - The Eastern Progress Online
Franklin Resources Inc. Grows Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX stock touches 52-week low at $13.26 amid market challenges - Investing.com Canada
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year LowShould You Sell? - MarketBeat
State Street Corp Has $72.59 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Fmr LLC Has $948,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
(SNDX) Technical Pivots with Risk Controls - Stock Traders Daily
Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial - Marketscreener.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Short Interest Update - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down – Time to Sell? - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.65 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
BNP Paribas Financial Markets Buys 16,663 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap DownTime to Sell? - MarketBeat
The Manufacturers Life Insurance Company Has $918,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals’ (SNDX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Y Intercept Hong Kong Ltd Buys 61,916 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX stock touches 52-week low at $14.99 amid market shifts By Investing.com - Investing.com South Africa
SNDX stock touches 52-week low at $14.99 amid market shifts - Investing.com Canada
SNDXSyndax Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Syndax Pharmaceuticals (NASDAQ:SNDX) Given Buy Rating at HC Wainwright - MarketBeat
While Syndax Pharmaceuticals (NASDAQ:SNDX) shareholders have made 85% in 5 years, increasing losses might now be front of mind as stock sheds 6.8% this week - Simply Wall St
Wellington Management Group LLP Cuts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Two Sigma Advisers LP Purchases 48,100 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj®? from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial - Marketscreener.com
Syndax's Revuforj Shows Breakthrough 100% Response Rate in AML Clinical Trial Data - StockTitan
Charles Schwab Investment Management Inc. Grows Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Quantbot Technologies LP Acquires Shares of 2,542 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax's Revuforj Shows Remarkable 82% Response Rate in Leukemia Clinical Trials at ASH Meeting - StockTitan
Verition Fund Management LLC Has $1.53 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
BlackRock, Inc. Acquires Additional Shares in Syndax Pharmaceuti - GuruFocus.com
(SNDX) Proactive Strategies - Stock Traders Daily
Syndax Pharmaceuticals (STU:1T3) Change In Prepaid Assets : €-6.79 Mil (TTM As of Sep. 2024) - GuruFocus.com
Syndax Pharmaceuticals (STU:1T3) COGS-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
Point72 Asset Management L.P. Sells 67,086 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX (Syndax Pharmaceuticals) FCF Margin % : -498.58% (As of Sep. 2024) - GuruFocus.com
Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
Parkman Healthcare Partners LLC Has $9.78 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals Awards Key Talent with Strategic Stock Options Package - StockTitan
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $37.64 Average PT from Analysts - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Eventide Asset Management LLC Buys New Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. announced that it expects to receive funding from Kyowa Hakko Kirin Co., Ltd. - Marketscreener.com
Syndax Pharmaceuticals, Inc. announced that it expects to receive $30 million in funding from Hercules Capital, Inc. - Marketscreener.com
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference - StockTitan
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by Propel Bio Management LLC - MarketBeat
Syndax Pharmaceuticals' SWOT analysis: stock outlook brightens on FDA approvals - Investing.com Canada
Long Term Trading Analysis for (SNDX) - Stock Traders Daily
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $38.00 Price Target at JPMorgan Chase & Co. - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Lowered by StockNews.com - Defense World
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):